Agenus Inc. (AGEN) is a publicly traded company in the Healthcare — Biotechnology industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Agenus Inc. is a clinical-stage biotechnology firm operating globally, dedicated to the discovery and development of immuno-oncology therapies. The company's innovative technological arsenal includes Retrocyte Display, a sophisticated antibody expression platform designed to identify fully human and humanized monoclonal antibodies, alongside other proprietary display technologies.
Analysis Summary
Agenus Inc. reported revenue of $114.2M in the most recent fiscal year, growing at a 5-year CAGR of 5.3%.
Trailing-twelve-month margins: gross margin 75.6%, operating margin 27.3%, net margin 69.3%.
At the current price of $7.21, AGEN trades at a P/E of 2.68 and an ROE of -38.12%. Market capitalisation stands at $300M.
Balance sheet quality for AGEN: current ratio of 0.4, net debt of $331.9M. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Cash flow quality is below average: free cash flow of -$158.9M represents -138166% conversion of reported net income. High conversion (above 90%) suggests earnings translate cleanly into cash; lower conversion may indicate working capital tightness or accounting timing differences.
Price
| Price | $7.21 |
| Market Cap | $300M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| P/E Ratio | 2.68 |
| Price / Book | -1.51 |
| EV / EBITDA | 2.34 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -38.12% |
| Return on Invested Capital | -129.48% |
| Return on Assets | 53.28% |
| Gross Margin | 75.63% |
| Operating Margin | 27.28% |
| Net Margin | 69.34% |
Financial Health
| Debt / Equity | -0.20 |
| Current Ratio | 0.34 |
What to look at in Biotech
Most small biotechs lose money. Analysing them with P/E makes no sense — look at cash and pipeline.
- Cash Runway — Months of cash at current burn rate. <18 months = urgent dilution risk
- Annual cash burn — Rate at which they burn operating cash. Compare with cash position to project runway
- Total Debt — Biotech with no revenue + debt = recipe for bankruptcy
- R&D / Market cap — How much they invest in pipeline vs the company value — research-intensity indicator
- Market cap / Cash — If it trades near its cash, the market assigns ~0 value to the pipeline — opportunity or trap
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| AGEN | Agenus Inc. | $300M | 2.68 | -38.1% | |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.6B | 29.76 | 6.46 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% | |
| RVMD | Revolution Medicines, Inc. | $41.7B | 15.96 | -96.4% |
Price Performance
| 1 month | -4.25% |
| 3 months | +140.33% |
| Year-to-date | +129.62% |
| 1 year | +58.46% |
| 3 years | -71.16% |
| 5 years | -93.82% |
52-Week Range
| 52-week High | $8.85 |
| 52-week Low | $2.71 |
| Avg Volume (90d) | 3.2M |
Related companies: ABOS · FATE · HURA · INO · IRD · PLRX · SEER
Explore sector: Healthcare · Biotechnology
More sections of AGEN: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks